65suppression and promotion. Science 331, 1565-1570 (2011). ４）Nishikawa H, Kato T, Tanida K, Hiasa A, Tawara I, Ikeda H, Ikarashi Y, Wakasugi H Kronenberg M, Nakayama T, Taniguchi M, Kuribayashi K, Old L J, Shiku H.; CD4+ CD25+ T cells responding to serologically-defined autoantigens suppress anti-tumor immune responses. Proc Natl Acad Sci USA. 100 : 10902-10906, 2003.５）Nishikawa H, Kato T, Tawara I, Saito K, Ikeda H, Kuribayashi K, Allen PM, Schreiber RD, Sakaguchi S, Old LJ, Shiku H. Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells. J Exp Med. 201 : 681-686, 2005.６）Nishikawa H, Kato T, Tawara I, Takemitsu T, Saito K, Wang L, Ikarashi Y, Wakasugi H, Nakayama T, Taniguchi M, Kuribayashi K, Old LJ, Shiku H. Accelerated chemically-induced tumor development mediated by CD4+ CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci USA. 102 : 9253-9257 2005.７）Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 102:18538-18543 2005.８）Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y and Sakaguchi S. Two FOXP3+CD4+ T-cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 22 (6) : 679-684 2016.９）Maeda Y, Nishikawa H, Sugiyama D, Ha D, Hamaguchi M, Saito T, Nishioka M, Wing JB, Adeegbe D, Katayama I and Sakaguchi S. Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals. Science. 346 (6216) : 1536-1540 2014.10）Kobayashi T, Kumagai S, Doi R, Afonina E, Koyama S, Nishikawa H. Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization. STAR Protoc. 3 (3) : 101557 2022.11）Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakaumra H, Takeuchi Y, Kochin, V, Itahashi K, Maeda Y, Matsui S, Shibahara,T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H. The PD-1 expression balance between effector and regulatory T cell predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 21 (11) : 1346-1358 2020.12）Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin, Y-T, Togashi Y, Kamada T, Irie T, Okumura G, Kohno H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakaumra H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Cida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, Nishikawa H. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 40 (2) : 201-218.e9 2022.13）Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada, Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K, Shintani Y, Okumura M, Tsuboi M, Nishikawa H. Blockade of EGFR improves responsiveness to PD1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol. 5 (43). pii : eaav3937 2020.文 献１）P. Ehrlich. Über den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd. 5, 273-290 (1909). ２）F. M. Burnet, Immunological aspects of malignant disease. Lancet 1, 1171-1174 (1967). ３）Schreiber, R. D., Old, L. J., Smyth, M. J. Cancer immunoediting : integrating immunity’s roles in cancer
元のページ ../index.html#67